Memantine
- Generic Name
- Memantine
- Brand Names
- Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21N
- CAS Number
- 19982-08-2
- Unique Ingredient Identifier
- W8O17SJF3T
- Background
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...
- Indication
Memantine is used to manage moderate to severe Alzheimer's dementia .
...
- Associated Conditions
- Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT00586573
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
Memantine and Cognitive Dysfunction in Bipolar Disorder
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00586066
- Locations
- 🇺🇸
Asher Depression Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Cedars Sinai Department of Psychiatry, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Memantine Treatment Study of Pathological Gambling
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- Yale University
- Target Recruit Count
- 29
- Registration Number
- NCT00585169
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome
- Conditions
- Interventions
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 94
- Registration Number
- NCT00584948
- Locations
- 🇺🇸
UC Davis MIND Institute, Sacramento, California, United States
🇺🇸University of Colorado Health Sciences Center, Aurora, Colorado, United States
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 554
- Registration Number
- NCT00566852
- Locations
- 🇺🇸
University Medical Center at Princeton, Princeton, New Jersey, United States
🇺🇸York Cancer Center at Apple Hill Medical Center, York, Pennsylvania, United States
🇺🇸Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 12
- Registration Number
- NCT00551161
- Locations
- 🇺🇸
The Litwin-Zucker Research Center, Manhasset, New York, United States
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
- Conditions
- Interventions
- First Posted Date
- 2007-10-18
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 81
- Registration Number
- NCT00545974
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University Hospitals of Cleveland / Case Medical Center, Cleveland, Ohio, United States
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2008-12-29
- Lead Sponsor
- Hospital Miguel Servet
- Target Recruit Count
- 64
- Registration Number
- NCT00505167
- Locations
- 🇪🇸
Hospital de Barbastro, Barbastro, Huesca, Spain
🇪🇸Hospital Royo Villanova, Zaragoza, Spain
🇪🇸Cenro de especialidades San José. Hospital Miguel Servet, Zaragoza, Spain
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 82
- Registration Number
- NCT00476242
- Locations
- 🇺🇸
STARS, New York, New York, United States
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Florida Atlantic University
- Target Recruit Count
- 60
- Registration Number
- NCT00476008
- Locations
- 🇺🇸
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.